Latest New Zealand Market News

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Tower Limited has raised its full-year profit guidance significantly, driven by lower-than-expected large event costs, even as it moderates its premium growth outlook.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

RMA Global Ltd reported a 13% revenue increase to $21.1 million in FY25, driven by growth in the US and New Zealand, alongside steady Australian performance. The company also recorded its first full-year positive operating cash flow, marking a significant financial turnaround.

Shine Justice Ltd reported a 4.4% rise in FY25 revenue to $204.4 million, alongside major legal settlements and leadership changes, signaling renewed growth momentum.

Austco Healthcare Limited reported a record $81.4 million in revenue for FY25, driven by organic growth and acquisitions including G&S Technologies. EBITDA jumped 62% to $13 million, reflecting strong operational leverage.

Michael Hill International reported steady FY25 results with flat revenue and modest profit improvement amid challenging market conditions. The company is focusing on brand repositioning, operational efficiency, and AI innovation as it navigates a complex retail environment.

Michael Hill International reported broadly flat FY25 financial results despite challenging retail conditions, with growth in Australia and Canada offset by ongoing difficulties in New Zealand. Strategic initiatives and early FY26 sales hint at cautious optimism.

GWA Group Limited reported modest revenue and earnings growth for FY2025, underpinned by strong Australian and UK markets, while announcing a $30 million on-market share buyback starting September 2025.

Amotiv Limited reported modest revenue growth and a slight EBITA decline in FY25, offset by a significant non-cash impairment and strong capital returns. The company anticipates growth in FY26 amid ongoing market headwinds.

Nick Scali Limited reported a solid FY25 underlying profit of $62 million, driven by strong ANZ sales and online growth, while UK operations continue to struggle amid store refurbishments and brand repositioning.

AMP reported a 9.2% increase in underlying net profit after tax to $131 million for the first half of 2025, driven by robust cashflow growth and steady performances across its wealth and banking divisions. The company also declared a 2.0 cents per share interim dividend, maintaining disciplined cost control amid ongoing strategic investments.